Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
NCT06297603 on ClinicalTrials.gov · last registry update 2026-07-20
Closed to new participants; the 320 already enrolled are still being followed. Due to report October 2026, alongside 33 other tracked readouts that quarter. Primary outcome, as filed: Change from Baseline in Hemoglobin A1c (HbA1c) (%). Sponsors move these dates routinely; any movement since this site started watching is listed below. It has been running since 15 March 2024 — 2 years so far. retatrutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- P3
- Drug
- retatrutide
- Sponsor
- Eli Lilly and Company
- Sponsor type
- Industry
- Enrollment
- 320
- Started
- 2024-03-15
- Primary completion
- 2026-10 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change from Baseline in Hemoglobin A1c (HbA1c) (%)
Conditions studied
Type 2 Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the retatrutide page for this molecule’s full trial and approval history.